Case Report: Treatment response of SQSTM1–ALK fusion lung adenocarcinoma to multiple ALK inhibitors
This is the first report of a patient with SQSTM1-ALK fusion who experienced different responses after treatment with alectinib, ensartinib, lorlatinib, and brigatinib. We hope that this case provides clinical evidence to guide treatment strategies for this rare variant and further supports the individualized application of ALK-tyrosine kinase inhibitors (TKIs) in patients with non-classical fusions.
Authors
- Yanbin Zhou (ORCID: https://orcid.org/0000-0002-0099-4258)
- Jing Zhang (ORCID: https://orcid.org/0000-0003-2966-9149)
- Ziying Lin (ORCID: https://orcid.org/0000-0002-4257-8981)
- Shaoli Li (ORCID: https://orcid.org/0000-0002-3513-2359)
- Jincui Gu (ORCID: https://orcid.org/0000-0002-3784-5440)
- Lixia Huang
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.3389/fphar.2025.1608080
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangdong Province